Literature DB >> 26233598

Acute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye.

Muhammad A Khan1, Muhammad Haroon, James T Rosenbaum.   

Abstract

Ankylosing spondylitis (AS) and related forms of spondyloarthritis (SpA) are associated with some extra-articular features, and the most common symptomatic association is with acute anterior uveitis (AAU). Thus, approximately 40 % of patients with AS will experience a sudden onset of a unilateral anterior uveitis sometime during the course of their disease. Patients with AAU, especially those who are HLA-B27 positive, should be questioned about inflammatory low back pain and also evaluated for other clinical features of SpA. Since a prolonged delay in diagnosis is common among SpA patients and occurrence of AAU may be the reason for their first interaction with medical care, occurrence of AAU presents a unique opportunity for identifying such undiagnosed SpA patients. Therefore, a novel evidence-based algorithm called Dublin Uveitis Evaluation Tool (DUET) has been proposed to guide ophthalmologists and primary care physicians to refer appropriate AAU patients to rheumatologists. In a large two-phase study, approximately 40 % of patients presenting with idiopathic AAU were noted to have undiagnosed SpA, and DUET algorithm was noted to have excellent sensitivity (96 %) and specificity (97 %). It has a positive likelihood ratio (LR) 41.5 and negative LR 0.03. In most instances, the eye inflammation responds well to corticosteroid and mydriatic eye drops and without the need for additional therapy. Use of oral corticosteroids is reserved for patients, especially with associated chronic inflammatory bowel disease or psoriatic arthritis presenting with bilateral, chronic, anterior, and/or intermediate uveitis, and this treatment is rarely needed for more than a couple of weeks. A very small percentage may be more refractory to such treatment and require potential novel therapies, including the use of tumor necrosis factor blockers.

Entities:  

Mesh:

Year:  2015        PMID: 26233598     DOI: 10.1007/s11926-015-0536-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  65 in total

Review 1.  Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications.

Authors:  Abdellah El Maghraoui
Journal:  Eur J Intern Med       Date:  2011-07-13       Impact factor: 4.487

2.  Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis.

Authors:  J M Benitez-Del-Castillo; J Garcia-Sanchez; T Iradier; A Bañares
Journal:  Eye (Lond)       Date:  2000-06       Impact factor: 3.775

Review 3.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

4.  Nibbling away at the diagnosis of idiopathic uveitis.

Authors:  James T Rosenbaum
Journal:  JAMA Ophthalmol       Date:  2015-02       Impact factor: 7.389

Review 5.  Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.

Authors:  E Miserocchi; I Pontikaki; G Modorati; M Gattinara; P L Meroni; V Gerloni
Journal:  Autoimmun Rev       Date:  2011-07-13       Impact factor: 9.754

6.  Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS.

Authors:  Ivette Essers; Sofia Ramiro; Carmen Stolwijk; Marc Blaauw; Robert Landewé; Désirée van der Heijde; Filip Van den Bosch; Maxime Dougados; Astrid van Tubergen
Journal:  Rheumatology (Oxford)       Date:  2014-09-17       Impact factor: 7.580

7.  The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients.

Authors:  Maxime Dougados; Maria-Antonietta d'Agostino; Joëlle Benessiano; Francis Berenbaum; Maxime Breban; Pascal Claudepierre; Bernard Combe; Patricia Dargent-Molina; Jean-Pierre Daurès; Bruno Fautrel; Antoine Feydy; Philippe Goupille; Véronique Leblanc; Isabelle Logeart; Thao Pham; Pascal Richette; Christian Roux; Martin Rudwaleit; Alain Saraux; Jean-Marc Treluyer; Désirée van der Heijde; Daniel Wendling
Journal:  Joint Bone Spine       Date:  2011-03-31       Impact factor: 4.929

8.  Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.

Authors:  Aurore Muselier; Philip Bielefeld; Samuel Bidot; Julien Vinit; Jean-François Besancenot; Alain Bron
Journal:  Ocul Immunol Inflamm       Date:  2011-10       Impact factor: 3.070

9.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

10.  A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.

Authors:  D Kane; L Stafford; B Bresnihan; O FitzGerald
Journal:  Rheumatology (Oxford)       Date:  2003-10-01       Impact factor: 7.580

View more
  12 in total

Review 1.  [Spondyloarthritides].

Authors:  M Rudwaleit
Journal:  Internist (Berl)       Date:  2017-07       Impact factor: 0.743

Review 2.  [Spondyloarthritides].

Authors:  M Rudwaleit
Journal:  Z Rheumatol       Date:  2017-12       Impact factor: 1.372

Review 3.  Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis.

Authors:  Rachael Stovall; Irene E van der Horst-Bruinsma; Shao-Hsien Liu; Tamara Rusman; Lianne S Gensler
Journal:  Nat Rev Rheumatol       Date:  2022-09-15       Impact factor: 32.286

Review 4.  Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?

Authors:  Traian-Costin Mitulescu; Marius Trandafir; Monica-Gabriela Dimăncescu; Radu-Constantin Ciuluvică; Viorela Popescu; Denisa Predețeanu; Sînziana Istrate; Liliana-Mary Voinea
Journal:  Rom J Ophthalmol       Date:  2018 Apr-Jun

Review 5.  The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future.

Authors:  Martina Biggioggero; Chiara Crotti; Andrea Becciolini; Elisabetta Miserocchi; Ennio Giulio Favalli
Journal:  Biomed Res Int       Date:  2018-10-14       Impact factor: 3.411

Review 6.  Immunological tests and their interpretation in uveitis.

Authors:  S R Rathinam; Ilknur Tugal-Tutkun; Mamta Agarwal; Vedhanayaki Rajesh; Merih Egriparmak; Gazal Patnaik
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

Review 7.  Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.

Authors:  Elsa How Shing Koy; Pierre Labauge; Athan Baillet; Clément Prati; Hubert Marotte; Yves-Marie Pers
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-09       Impact factor: 5.346

Review 8.  In Vivo Confocal Microscopy of the Human Cornea in the Assessment of Peripheral Neuropathy and Systemic Diseases.

Authors:  Ellen F Wang; Stuti L Misra; Dipika V Patel
Journal:  Biomed Res Int       Date:  2015-12-07       Impact factor: 3.411

9.  A referable clinical pattern of spondyloarthritis-associated uveitis.

Authors:  Costin Traian Mitulescu; Claudiu Costinel Popescu; Constantin Laurențiu Oprea; Denisa Predețeanu; Sînziana Istrate; Radu Ciuluvică; Liliana-Mary Voinea
Journal:  Rom J Ophthalmol       Date:  2018 Apr-Jun

10.  The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.

Authors:  Irene van der Horst-Bruinsma; Rianne van Bentum; Frank D Verbraak; Thomas Rath; James T Rosenbaum; Maria Misterska-Skora; Bengt Hoepken; Oscar Irvin-Sellers; Brenda VanLunen; Lars Bauer; Martin Rudwaleit
Journal:  RMD Open       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.